Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (opent nieuw venster)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Bron‎: Cancer 2013;119(21):3784-7.

Geïndexeerd‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (opent nieuw venster)

Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia? (opent nieuw venster)

Chakrabarti S, Varma S, Singh S, Kumari S

Bron‎: Eur J Haematol 1998;60(5):313-4.

Geïndexeerd‎: PubMed 9654162

DOI‎: 10.1111/j.1600-0609.1998.tb01046.x

https://www.ncbi.nlm.nih.gov/pubmed/9654162 (opent nieuw venster)

The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia. (opent nieuw venster)

Delaney M, Matthews DC, Gernsheimer TB

Bron‎: Pediatr Blood Cancer 2017;64(12):e26641.

Geïndexeerd‎: PubMed 28544698

DOI‎: 10.1002/pbc.26641

https://www.ncbi.nlm.nih.gov/pubmed/28544698 (opent nieuw venster)

Preliminary experience with epsilon aminocaproic acid for treatment of intractable upper tract hematuria in children with hematological disorders. (opent nieuw venster)

Kaye JD, Smith EA, Kirsch AJ, Cerwinka WH, Elmore JM

Bron‎: J Urol 2010;184(3):1152-7.

Geïndexeerd‎: PubMed 20650477

DOI‎: 10.1016/j.juro.2010.05.020

https://www.ncbi.nlm.nih.gov/pubmed/20650477 (opent nieuw venster)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (opent nieuw venster)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Bron‎: Leuk Lymphoma 1995;19(1-2):141-4.

Geïndexeerd‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (opent nieuw venster)

Pediatric off-label use of recombinant factor VIIa. (opent nieuw venster)

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Bron‎: Pediatrics 2009;123(3):1066-72.

Geïndexeerd‎: PubMed 19255041

DOI‎: 10.1542/peds.2008-1685

https://www.ncbi.nlm.nih.gov/pubmed/19255041 (opent nieuw venster)

Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience. (opent nieuw venster)

Bhat S, Yadav SP, Anjan M, Dinand V, Sachdeva A.

Bron‎: Indian J Pediatr 2011;78(8):961-8.

Geïndexeerd‎: PubMed 21328080

DOI‎: 10.1007/s12098-011-0364-6

https://www.ncbi.nlm.nih.gov/pubmed/21328080 (opent nieuw venster)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (opent nieuw venster)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Bron‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Geïndexeerd‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (opent nieuw venster)

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label. (opent nieuw venster)

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL

Bron‎: Pediatr Blood Cancer 2016;63(10):1822-8.

Geïndexeerd‎: PubMed 27232114

DOI‎: 10.1002/pbc.26082

https://www.ncbi.nlm.nih.gov/pubmed/27232114 (opent nieuw venster)

Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia. (opent nieuw venster)

Das P, Carcao M, Hitzler J

Bron‎: Pediatr Blood Cancer 2006;47(2):206-9.

Geïndexeerd‎: PubMed 16007583

DOI‎: 10.1002/pbc.20467

https://www.ncbi.nlm.nih.gov/pubmed/16007583 (opent nieuw venster)

A comprehensive review of rFVIIa use in a tertiary care pediatric center. (opent nieuw venster)

Heller M, Lau W, Pazmino-Canizares J, Brandão LR, Carcao M

Bron‎: Pediatr Blood Cancer 2008;50(5):1013-7.

Geïndexeerd‎: PubMed 17960639

DOI‎: 10.1002/pbc.21375

https://www.ncbi.nlm.nih.gov/pubmed/17960639 (opent nieuw venster)

Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. (opent nieuw venster)

Kurekci AE, Atay AA, Okutan V, Yavuz ST, Ozcan O

Bron‎: Blood Coagul Fibrinolysis 2005;16(2):145-7.

Geïndexeerd‎: PubMed 15741803

DOI‎: 10.1097/01.mbc.0000161569.66764.70

https://www.ncbi.nlm.nih.gov/pubmed/15741803 (opent nieuw venster)

Off-label use of recombinant factor VIIa in pediatric patients. (opent nieuw venster)

McQuilten ZK, Barnes C, Zatta A, Phillips LE; Haemostasis Registry Steering Committee

Bron‎: Pediatrics 2012;129(6):e1533-40.

Geïndexeerd‎: PubMed 22641758

DOI‎: 10.1542/peds.2011-2561

https://www.ncbi.nlm.nih.gov/pubmed/22641758 (opent nieuw venster)

Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) registry (2004-2008). (opent nieuw venster)

Neufeld EJ, Saxena K, Kessler CM, Cooper DL; HTRS Investigators

Bron‎: Pediatr Blood Cancer 2013;60(7):1178-83.

Geïndexeerd‎: PubMed 23335449

DOI‎: 10.1002/pbc.24472

https://www.ncbi.nlm.nih.gov/pubmed/23335449 (opent nieuw venster)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (opent nieuw venster)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Bron‎: Med Oncol 2010;27(1):16-9.

Geïndexeerd‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (opent nieuw venster)

Successful treatment of acute lymphoblastic leukemia with l-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child. (opent nieuw venster)

Ucar C, Caliskan U

Bron‎: Pediatr Hematol Oncol 2006;23(4):339-45.

Geïndexeerd‎: PubMed 16621776

DOI‎: 10.1080/08880010600631987

https://www.ncbi.nlm.nih.gov/pubmed/16621776 (opent nieuw venster)

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. (opent nieuw venster)

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Bron‎: Pediatr Hematol Oncol 2008;25(4):301-11.

Geïndexeerd‎: PubMed 18484474

DOI‎: 10.1080/08880010802016904

https://www.ncbi.nlm.nih.gov/pubmed/18484474 (opent nieuw venster)

The use of DDAVP in children with bleeding disorders. (opent nieuw venster)

Ben-Ami T, Revel-Vilk S

Bron‎: Pediatr Blood Cancer 2013;60 Suppl 1:S41-3.

Geïndexeerd‎: PubMed 23109357

DOI‎: 10.1002/pbc.24335

https://www.ncbi.nlm.nih.gov/pubmed/23109357 (opent nieuw venster)

Treatment of refractory thrombocytopenic bleeding with 1-desamino-8-D-arginine vasopressin (desmopressin). (opent nieuw venster)

Kobrinsky NL, Tulloch H

Bron‎: J Pediatr 1988;112(6):993-6.

Geïndexeerd‎: PubMed 3373409

DOI‎: 10.1016/s0022-3476(88)80234-8

https://www.ncbi.nlm.nih.gov/pubmed/3373409 (opent nieuw venster)

The use of Tachosil as hemostatic sealant in nephron sparing surgery for Wilms tumor: preliminary observations. (opent nieuw venster)

Mele E, Ceccanti S, Schiavetti A, Bosco S, Masselli G, Cozzi DA

Bron‎: J Pediatr Surg 2013;48(3):689-94.

Geïndexeerd‎: PubMed 23480936

DOI‎: 10.1016/j.jpedsurg.2013.01.019

https://www.ncbi.nlm.nih.gov/pubmed/23480936 (opent nieuw venster)